Physician profile
Jeffrey Ogbara
NPI 1528112513
$28,790.13
in general payments reported to CMS, 2019-2025
37 companies · $3,466 in 2025
The $3,466 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $5,201 · 2020: $988 · 2021: $1,906 · 2022: $2,041 · 2023: $10K · 2024: $4,813 · 2025: $3,466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $9,215 · Food and Beverage: $8,939 · Consulting Fee: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $9,215.08 |
| Food and Beverage | $8,938.59 |
| Consulting Fee | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $11,049.04 | 2021-2025 | Corevalve Evolut R, Symplicity G3, Onyx Frontier |
| Abbott Laboratories | $6,136.14 | 2019-2025 | Aveir, Navitor, Mitraclip |
| Medtronic Vascular, INC. | $2,442.85 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $2,056.92 | 2019-2025 | Lifevest |
| Teleflex LLC | $1,527.33 | 2022-2025 | Manta, Guideliner |
| Penumbra, INC. | $1,011.61 | 2020-2025 | Indigo System |
| Stryker Corporation | $671.18 | 2025 | Clottriever Bold Catheter, Artix Mt |
| Novartis Pharmaceuticals Corporation | $436.45 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $428.50 | 2019-2024 | Xarelto |
| Abiomed | $308.63 | 2021-2025 | Impella |
| Astrazeneca Pharmaceuticals LP | $282.17 | 2019-2023 | Farxiga |
| Boston Scientific Corporation | $201.59 | 2019-2024 | Watchman Flx |
| Edwards Lifesciences Corporation | $191.87 | 2024-2025 | Sapien 3 Ultra Resilia |
| Pfizer INC. | $186.13 | 2019-2025 | |
| Arrow International, INC. | $183.92 | 2024 | Manta |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cathworks, INC. | $181.26 | 2022 | |
| Inari Medical, INC. | $172.68 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Impulse Dynamics (USA) INC. | $168.61 | 2021-2024 | Optimizer |
| E.R. Squibb & Sons, L.L.C. | $166.82 | 2019-2025 | Eliquis, Camzyos |
| Shockwave Medical, INC | $156.15 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Cardiovascular Systems INC. | $146.33 | 2019 | |
| Amgen INC. | $135.88 | 2019-2024 | Repatha |
| Janssen Scientific Affairs, LLC | $119.60 | 2022 | |
| Amarin Pharma, INC. | $63.41 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $57.99 | 2021-2023 | Verquvo |
| Cvrx, INC. | $52.11 | 2024 | Barostim Neo System |
| Lexicon Pharmaceuticals, INC. | $50.76 | 2024 | |
| W. L. Gore & Associates, INC. | $48.57 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $30.92 | 2024 | Arcalyst |
| Inspire Medical Systems, INC. | $20.45 | 2024 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $18.43 | 2024 | |
| Alnylam Pharmaceuticals INC. | $16.30 | 2025 | Amvuttra |
| Kiniksa Pharmaceuticals, LTD. | $16.24 | 2023 | Arcalyst |
| Chiesi USA, INC. | $15.18 | 2022 | |
| Astellas Pharma US INC | $14.05 | 2019 | |
| Novo Nordisk INC | $12.90 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,350.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Ogbara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.